Primary diffuse large B cell lymphoma of the uterus: A case report and literature review

Wang Q1, Wang W2, Fan W1, Zhou Q1, Yang L1 and Liu X1

1Department of Radiology, Binzhou Medical University Hospital, Binzhou Shandong, China
2Binzhou Medical University, Yantai Shandong, China

Abstract

Objective: This report reports a case of primary uterine lymphoma that was initially misdiagnosed as uterine fibroids/uterine sarcomas. Through case report, the recognition of primary uterine lymphoma is strengthened. If MRI shows very high DWI signal in the tumor in future clinical work, it should be considered whether it is lymphoma.

Background: A 64-year-old woman who was found to have an abdominal mass on ultrasound was initially misdiagnosed with a uterine fibroid/uterine sarcoma. Clinical evidence: Pelvic MRI showed multiple soft tissue mass shadows in the pelvic cavity, and the larger shadows were approximately 14.2 cm × 9.7 cm × 15.6 cm, with clear boundaries dominated by an iso-long T1 and slightly longer T2, locally visible nodular long T2 and short T2 signal foci, and obvious high signals on DWI and decreased ADC signals. The enhancement of the densification was obviously non-uniform. The immunohistochemical results were positive for CD20, LCA, PAX-5, CD43 +, c-myc, bcl2 and bcl6 and negative for SAM, Desmin, Myo D1, MPO, CD99, CD30, CD23, S-100, and CD10. The majority (90%) of tumor cells were positive for Ki-67. The diagnosis was a diffuse large b-cell lymphoma. Preoperative diagnosis of primary lymphoma of the uterus is difficult in clinical situations. Primary female genital system lymphoma (PFGSL) of the reproductive system is a rare disease, accounting for only 0.21-1.1% of extranodal lymphoma, accounting for approximately 50% of cases [2]. Frequently occurring parts include the ovary, uterus, vagina and vulva. This paper reports a case of primary lymphoma of the uterus that was misdiagnosed as uterine fibroids.

Case report

Clinical evidence: The female patient, who was 64 years old, was found to have uterine fibroids by a physical examination 23 years ago. Natural menopause occurred 11 years ago, with no abnormal vaginal bleeding after menopause. Over the past 2 months, the tumor in the lower abdomen was spontaneously palpable and hard, and a color ultrasound examination performed 4 days ago suggested a hypoecho in the pelvic cavity, possibly fibroids with diameters of approximately 10 cm. The patient had no nausea and vomiting, occasional abdominal distension, no diarrhea, no abdominal pain, discomfort in the lumbosacral region, anorectal heaving and distension in January, as well as no frequent urination, urgent urination or pain; no insensitivity to urination; and no abnormal leucorrhea.

Gynecological examination: vulva development is normal; married and delivered; vagina unobstructed, smooth wall; cervical atrophy, incomplete exposure due to tumor compression, smooth palpation surface, no lift pain and sway pain; palpation of the uterus is not clear; the pelvic cavity touches a hard surface; irregular, movement is acceptable; the upper edge reaches the level of the umbilicus, no obvious tenderness; mild tenderness in the left adnexal region. No obvious abnormalities were found in the right accessory area.

Intraoperative observations: the uterus increases with size, such as during pregnancy, and congestion, with a brittle, anterior wall only exposed at the bottom of the palace; most of the anterior wall had edema thickening and hardening of the urinary bladder as well as invasion adhesion coverage; double accessories were not observed, but there was an obvious abnormal appearance; the rectum anterior wall had bumps that were approximately 5cm in diameter; the oppressed rectum was larger than the other small intestine segments and was mesenteric was the greater omentum 0.88 cm in size with multiple lesions; most of the lines indicate a uterus excision and double appendix resection.

Imaging findings: there were multiple large soft tissue shadows in the pelvic cavity, and the larger ones were approximately 14.2 cm × 9.7 cm × 15.6 cm in size; the boundary was still clear. The lesions were characterized by an equal length T1 and slightly longer T2, with locally visible nodular long T2 and short T2 signal foci. The DWI signal was obviously high and the ADC signal was reduced. The part of the enhancement showed obvious non-uniform reinforcement. The uterus

*Correspondence to: Liu X, Department of Radiology, Binzhou Medical University Hospital, Binzhou Shandong, China, Tel: +13356286368; E-mail: lxj6513@163.com

Key words: diffuse large B-cell lymphoma (DLBCL), Primary female genital system lymphoma (PFGSL), extranodal lymphoma, diagnosis

Received: December 03, 2018; Accepted: December 18, 2018; Published: January 03, 2019
was imbedded, the normal musculoskeletal structure was unclear, and the posterior part of the lesion was closely related to the rectum, as shown in Figure 1.

Pathology findings: The uterine volume was approximately 6×6×5.5 cm, and the endometrium was smooth with a mass under the endometrium, with a volume of 14×13×10.5 cm. There were numerous white nodules in the left mesosalpinx, with a diameter of 0.1-1.3 cm, and the volume of the left ovary was 1.7×0.8×0.6 cm. There was one gray-white nodule in the mesosalpinx and the right ovary area each, a volume of 2.7×1.7×0.8 cm and 3.5×3.5×2.5 cm, respectively. The cut surface was all soft and gray-red, and there was 1 white fish-like nodule (mesenteric metastasis), with a volume of 3×2.5×1.2 cm, as shown in Figure 2. We concluded that the masses represented diffuse large b-cell lymphoma.

Immunohistochemical: CD20 +, PAX-5+, CD3 -, CD5 -, CD43 +, CD10 -, the Bcl - 6 part +, scattered in weak MUM - 1 +, the Bcl - 2 +, cyclin D1 scattered +, CD23 -, CD30 -, c - myc part weak +, LCA +, CK -, Vimentin part +, SMA -, Desmin -, MPO -, Myo D1 -, Myogenin -, CD99 -, S-100 -, ki - 67 approximately 90% (Table 1).

Discussion

PFGLS is a rare disease that is mostly associated with non-Hodgkin's lymphoma, usually diffuse large b-cell lymphoma [4]. Nasioudis et al. [3] found that 667 cases in the SEER database were primary tumors in female genital lymphoma from 1988 to 2012. The most common histological subtypes were diffuse large B cells (59.8%) and follicular lymphoma (11.9%), which occurred in the ovary (37%), cervix (21.4%) and uterus (16.5%). Of these, 62.8% underwent surgery. The majority of primary uterine DLBCL originated from endometrial stroma. The discovery of DLBCL in uterine fibroids has been reported only twice before. Zhao [5] reported a 73-year-old female with an endometrial mass of 17 cm, which was diagnosed as a primary DLBCL. The DLBCL originated from uterine fibroids, and the tumor extended to the adjacent myometrium, including intravascular tumor thrombosis. Alexandra Martin [2] reported a case with a uterine mass of 10×8×5.8 cm...
Gene expression profiles (GEP) can distinguish between DLBCL in of limited ability, recent attention has turned to the molecular factor. Considering the clinical characteristics of prognosis, rituximab combined with cyclophosphamide, doxorubicin and radiotherapy according to the patient’s situation. Diffuse large b-cell lymphoma and is often treated with surgery and chemotherapy combined with Immuno-histochemical evaluation, tumor cells were found to be positive in follicular, Burkitt’s, follicular, and Hodgkin’s lymphomas. Occasionally expressed in uterine smooth muscle tumors

Table 1. Description of the immunohistochemistry and its significance [2]

| Marker      | Description                        | Status in our patient | Significance                                      |
|-------------|------------------------------------|-----------------------|--------------------------------------------------|
| CD20        | Pan-B-cell antigen                  | +                     | Indicates B-cell origin                           |
| CD43        | Pan-T-cell antigen                  | +                     | Indicates T-cell origin                           |
| CD30        | Tumor necrosis factor receptor; lymphocyte activation antigen | -                     | Used in diagnosis of Hodgkin’s lymphoma           |
| CD3         | pan-T-cell antigen                  | -                     | Indicates T cell origin of lymphocytes            |
| BCL6        | Germinal center marker              | +                     | Positive in T-cell, DLBCL, Burkitt’s, Follicular, and Hodgkin’s lymphomas |
| BCL2        | Proto-oncogene; prevents cells form | +                     | Positive in follicular, Burkitt’s, DLBCL, Hodgkin’s, Mantle Cell, and Marginal Zone lymphomas |
| MMP1        | Intra- and post-germinal center B-cell marker | +                     | Helps distinguish between germinal center and non-germinal center DLBCL |
| Ki-67       | Lable, non-histone nuclear protein. Marker of cell proliferation | + (90%)               | Higher nuclear staining indicates more aggressive tumor |
| CD10        | Cell membrane metalloepitidase; germinal center marker | -                     | Positive in germinal center DLBCL, Burkitt’s, Follicular, Hairy cell lymphomas. Occasionally expressed in uterine smooth muscle tumors |
| Desmin      | Expressed by smooth muscle cells    | -                     | Indicates smooth muscle origin                    |
| S100        | Cytoplasmic EF-hand Ca2+ -binding protein | -                     | Indicates smooth muscle origin                    |
| Smooth muscle actin (SMA) | Expressed by smooth muscle cells | -                     | marker of neural tissue and melanocytic differentiation |

The GEP is not routinely available in clinical practice, the world health organization (WHO) allows the use of CD10, BCL2 and BCL6 (Hans algorithm) or similar pattern distinguish between GCB and ABC immunohistochemical method, although their accuracy is limited [14]. The uterine DLBCL showed a worse prognosis than other lymphomas. Takuya [15] reported that Long-term intrauterine device (IUD) implantation and poor intrauterine environment may lead to chronic inflammation in the uterus, which resulted in DLBCL associated with chronic inflammation. Tarec [16] believes that DLBCL involvement in the uterus is associated with a high risk of secondary central nervous system involvement, and these patients should be considered for central nervous system staging and prevention. It was reported that the cumulative incidence of central nervous system recurrence was 44% in 4 years of uterine DLBCL (ovarian lymphoma with no recurrence), which would classify it as a high-risk site. The particular independent risk of lymphoma in the central nervous system may be related to the MCD (MYD88/CD79B mutation) genomic subtype that is prevalent in these lymphomas [14]. Through this case report, the recognition of primary lymphoma of uterus was deepened, misdiagnosis was reduced, and diagnostic rate was improved.

References

1. Cubo AM, Soto ZM, Cruz MA, Doyague MJ, Sancho V, et al. (2017) Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone: A case report. Medicine (Baltimore) 96: e6846. [Crossref]
2. Martin A, Medlin E (2017) Primary, non-germinal center, double-expressor diffuse large B cell lymphoma confined to a uterine leiomyoma: A case report. Gynecol Oncol Rep 22: 78-81. [Crossref]
3. Nasioudis D, Kampaki JS, Frey M, Wiltkin SS, Holcomb K (2017) Primary lymphoma of the female genital tract: An analysis of 697 cases. Gynecol Oncol 145: 305-309. [Crossref]
4. Sammana M, van Poppel G (2011) Primary malignant lymphoma of the uterus: A case report and review of the literature. Case Rep Oncol 4: 560-563. [Crossref]
5. Zhao L, Ma Q, Wang Q, Zeng Y, Luo Q, et al. (2016) Primary diffuse large B cell lymphoma arising from a leiomyoma of the uterine corpus. Diagn Pathol 11: 9. [Crossref]
6. Regalò A, Caseiro L, Pereira E, Cortes J (2016) Primary lymphoma of the uterine cervix: A rare constellation of symptoms. BMJ Case Rep 2016. [Crossref]
7. Patro MK, Bal AK, Santosh T, Mishra B (2016) Primary Non-Hodgkin’s Lymphoma of Diffuse Large B-Cell Phenotype [DLBCL] of Uterine Corpus: A Rare Case Report with Brief Review of the Literature[J]. J Obstet Gynaecol India 66: 675-678. [Crossref]
8. Chen R, Yu Z, Zhang H, Ding J, Chen B (2015) Primary malignant lymphoma of the uterus and broad ligament: a case report and review of literature. *Onco Targets Ther* 8: 265-268. [Crossref]

9. Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K (2017) Fertility-preserving surgery for advanced stage ovarian germ cell tumors. *Gynecol Oncol* 147: 493-496. [Crossref]

10. Zhu YL, Qian HF, Shen J (2012) MRI diagnosis of primary lymphoma of uterus. *Modern Pract Med* 2012: 1038-1039.

11. Vang R, Medeiros LJ, Deavers MT (2006) Current problems with staging lymphomas involving the ovary. *Am J Surg Pathol* 30: 1202-1203. [Crossref]

12. Shen H, Wei Z, Zhou D, Zhang Y, Han X, et al. (2018) Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. *Oncol Lett* 16: 1602-1614. [Crossref]

13. Upanal N, Enjeti A (2011) Primary lymphoma of the uterus and cervix: two case reports and review of the literature. *Aust N Z Obstet Gynaecol* 51: 559-562. [Crossref]

14. Li Y, Cui W, Woodroof JM, Zhang D (2016) Extraneal B Cell Lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review. *Ann Clin Lab Sci* 46: 213-218. [Crossref]

15. Shimizu T, Hatanaka K, Kaneko H, Shimada T, Iimada K (2017) Primary uterine diffuse large B-cell lymphoma (DLBCL) in a patient with prolonged insertion of intrauterine device (IUD). *Int J Hematol* 106: 138-140. [Crossref]

16. El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, et al. (2016) Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. *Br J Haematol* 175: 876-883. [Crossref]